Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population

Inclusion Criteria: * Diagnosis of COPD with 20% ≤ FEV1 ≤ 45% and FEV1/FVC \< 70% (post-bronchodilator) * History of long-term smoking, but non-smoking for a minimum of 2 months prior to study consent * Patient is a candidate for bronchoscopy * Patient agrees to all follow-up and provides written informed consent. Exclusion Criteria: * Presence of lung or chest implants (eg. metal stent, valves, coils) * Pregnancy * Pre-existing pulmonary hypertension * Patient has a pacemaker, internal defibrillator, or other implantable electronic device * Inappropriate bronchial anatomy for procedure (per CT scan) * Previous abdominal surgical procedures on stomach, esophagus or pancreas * Previous treatment with TLD Therapy (in same areas) * Known allergy to bronchoscopy or general anesthesia medications * Inability to tolerate single lung ventilation for at least 2 min, 30 sec * Patient has a GCSI score of ≥ 18 at time of screening visit